share_log

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65

Benzinga ·  Apr 8 07:37

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 to $65.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment